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E-mail address: Julia.Lowe@sunnybrook.ca (J. LowAims: To assess a group-based cognitive behaviour therapy [CBT] program in diabetes.
Methods: Sixty people with diabetes were randomly allocated to either immediate (29) or 3 months
delayed (31) CBT groups.
Results: DASS scores were reduced by 0.37 standardised [effect-size] units [P < 0.01], with a tendency for
more marked reductions in anxiety and stress [0.60] among those for whom treatment had been delayed
whose HbA1C fell by 0.93% . ADDQoL scores also improved in the short-term but these changes did not
persist at 6 months.
Conclusions: The CBT program led to short-term improvements in anxiety, depression, stress and quality
of life.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
In Australia, 7.4% of the adult population has diabetes [1]. Dia-
betes complications are the major cause of associated morbidity
and mortality, hence the major aim of diabetes management is
to prevent or minimise complications [2]. Diabetes is a demand-
ing illness and having co-morbid anxiety or depression makes it
all the more difﬁcult to carry out the activities recommended to
achieve better diabetic control and thereby reduce risk of compli-
cations [3]. Many of the clinical interventions in diabetes treat-
ment programs are group based in format and range from self-
management training to psychotherapy [4]. In type 2 diabetes,
psychological interventions have already been shown to result
in improvements in HbA1C [3,6] and depression outcomes
[3,5,7]. There are, however, conﬂicting reports on psychosocial
outcomes and no studies of quality of life post psychological
intervention [4].
The Royal Newcastle Hospital [RNH] is a public teaching hospi-
tal providing free outpatient care for most of the people with dia-
betes in the sixth largest city in Australia. Its diabetes outpatient
population has a higher prevalence of anxiety and depression com-
pared to the general public [8]. Aware of this, we designed a study
to assess whether a cognitive behaviour therapy [CBT] program for
diabetes clinic patients was acceptable, improved quality of life
and produced measurable change in levels of depression, anxiety
and stress.ellitus. Published by Elsevier Ltd.
: +1 416 480 4250.
e).
O2. Methods
2.1. Recruitment of subjects
People who attended the Hunter Area Diabetes Services RNH
Diabetes Outpatient Clinic were offered written information about
participating in the Dealing with Anxiety [DWA] Group CBT Pro-
gram. Those who consented to phone contact were sent informa-
tion packages by mail. Consenting volunteers were then
randomly allocated to an immediate intervention CBT group or a
CBT group in 3 months time [delayed intervention group]. There
was no formal screening test for co-morbid psychiatric disorder
but all patients were evaluated by a family practitioner experi-
enced in psychiatry. One patient was excluded because of a border-
line personality. This study was approved by the Hunter New
England Research Ethics Committee clinical trial registration num-
ber NCT00659932.
2.2. Intervention
The DWA CBT Program comprised seven group sessions: an
initial 5 h session followed by six 3 h sessions over a 3 months
period. The core program was cognitive behavioural therapy
adapted from the Generalised Anxiety Disorder Patient Treatment
Manual, of St. Vincent’s Hospital, Sydney with the addition, of
diabetes speciﬁc resources. The intervention was delivered by
one person.
Participants were asked to complete individual homework tasks
between group sessions, based on the session content. Each
participant also had an individual consultation, ranging from 1 topen access under CC BY-NC-ND license.
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Individuals with Depression Anxiety Stress Scale [DASS] [9] scores
in the severe or extremely severe ranges were encouraged to con-
sult their family General Practitioner for additional support.
2.3. Data collection
There were ﬁve points of data collection at three monthly
intervals, timed to coincide with routine HbA1C collections and
the 14 weeks duration of the CBT program. The data collected in-
cluded haemoglobin A1C [HbA1C, the percentage of glycosylated
haemoglobin in the blood], DASS and Diabetes Quality of Life
[ADDQoL] [10] questionnaires at each timepoint. Demographic
details were collected and thyroid stimulating hormone [TSH]
levels measured at study entry. Of the 61 patients enrolled,
one was excluded because of a personality disorder and com-
plete data were collected from 55 at pre-treatment, 35 post-
CBT 29 at 3 months post-treatment and 31 at 6 months post-
treatment. Patients were excluded if they missed two or more
sessions.
2.4. Measures
Demographics included the basic descriptive data of age, gender,
BMI, age ceased full time education, years since diagnosis of diabe-
tes, type of treatment [lifestyle, oral medication, insulin], number
of diabetes related complications and number of diabetes associ-
ated co-morbidities.
Evaluation of satisfaction with the conduct of the sessions was
completed after each of the seven sessions, using a participant
feedback questionnaire with eight items to assess process [e.g.,
comfort with conduct of group] and content [e.g., appropriate-
ness/value of session content, identiﬁcation of content needing
improvement]. General comments were also invited.
Psychological instruments used were the DASS and the ADDQoL.
The DASS is a set of three 14 item self-report scales designed to
measure the negative emotional states of depression, anxiety and
stress [nine Subjects are asked to use a 4 point severity/frequency
scale to rate the extent to which they have experienced each state
over the past week. As the essential development of the DASS was
carried out with non-clinical samples, it is suitable for screening
normal adults. The principal clinical value of the DASS is to clarify
the locus of emotional disturbance and to assess the severity of the
core symptoms of depression, anxiety and stress. It also gives
recommended cut-offs for conventional severity levels [normal,
mild, moderate, severe, extremely severe]. It does not measure
suicidality.
The ADDQoL is a 20 item questionnaire that measures perceived
quality of life in general [QI, two items] and in relation to living
with diabetes [QII, 18 items] [10]. It weights each score by the per-
son’s rating of importance [from 9 to +9], reﬂecting the most neg-
ative to the most positive impact of diabetes on that domain. A
zero score means no impact of diabetes on the person for that do-
main and/or the domain is not important to that person. An aver-
age of these scores measures the overall impact of diabetes on an
individual’s perceived quality of life.
2.5. Statistical analysis
Data analysis was performed by the second author [TL], using
Excel and SPSS software [version 14.0, SPSS Inc., Chicago, Ill,
USA], and comprised two main elements: ﬁrstly, an analysis of
the initial treatment effect [using data from time 1 and time 2];
and, secondly, an examination of the persistence of treatment ef-
fects and the consequences of delaying treatment [using data that
were re-aligned to reﬂect the same treatment and follow-upphases]. Initial treatment effects were assessed using 2  [2]
repeated measures ANOVAs [treatment status by time], where
the ‘‘treatment group” received immediate treatment [IM] [i.e.,
pre- to post-treatment changes] and the ‘‘control group” consisted
of the delayed treatment group [DL] [i.e., baseline to pre-treatment
changes]. In order to demonstrate whether the treatment effect
persisted, the data were re-aligned into the four main phases
[pre- and post-treatment, and 3- and 6-month follow-ups]. In view
of the ﬂuctuations in sample size across these phases, planned
comparisons were examined between all pairs of phases [from re-
peated measures ANOVAs].
As a partial control for the number of statistical tests, the
threshold for signiﬁcance was set at P < 0.01. Given the pilot nat-
ure of this study, we also report as ‘‘possible trends” [i.e., for
consideration in future studies] statistical tests in the range
P > 0.01 and <0.10. To facilitate discussion, differences are also
expressed in standardised [effect-size] units, which were ob-
tained by dividing the raw differences by the relevant grand
standard deviation for the outcome of interest [based on all
available data]. We also conducted a parallel series of traditional
intention-to-treat [ITT] [11]. For these analyses, missing follow-
up data were imputed by carrying forward the last available
observation.3. Results
3.1. Sample characteristics
The characteristics of the patients were as follows: age [n = 60],
mean 57.1, range 22–84; gender [n = 60], 35 male, 25 female; BMI
[n = 45], mean 34.5, range 19.5–62.3; age ceased full time educa-
tion [n = 56], mean 16.1, range 11–28; years since diagnosis of dia-
betes [n = 56], mean 14.3, range 1–45; number of diabetes related
complications [including eyes, kidneys, blood vessels, feet, limbs,
sexual dysfunction] [n = 57], mean 1.77 range 0–5; number of dia-
betes associated co-morbidities [including hypertension, obesity,
lipids disorders] [n = 57], mean 1.84, range 0–3. For the majority
of people who failed to complete the programme either ill health
or conﬂicting appointments led to automatic exclusion for missing
two or more sessions.
3.2. Initial treatment effect [Table 1]
3.2.1. HbA1C
Haemoglobin A1C rose signiﬁcantly from time 1 to time 2
[P = 0.003], reﬂecting a progression of the disease over time.
3.2.2. ADDQoL
Although there was no change in general quality of life [ADD-
QoL – QI], there was an overall improvement in diabetes speciﬁc
quality of life [ADDQoL – QII] between time 1 and time 2 [P =
0.006], probably reﬂecting time since diagnosis.
3.2.3. DASS
There were no signiﬁcant overall changes in DASS scores be-
tween time 1 and time 2. However, the control group [DL] reported
a worsening of symptoms on all three DASS measures, while the
treatment group [IM] revealed modest improvements, which is re-
ﬂected in the interaction terms trending towards statistical signif-
icance [depression, P = 0.073; anxiety, P = 0.092; stress, P = 0.049].
Expressed in standardised units, the largest differential improve-
ment occurred on the depression scale, with the IM group improv-
ing by 0.39 and the control group deteriorating by 0.15, a net
difference of 0.54 [conventionally regarded as a moderate treat-
ment effect].
Table 1
Analysis of initial treatment effects: CBT program [immediate, IM] vs. waiting list [delayed, DL].
Outcome measure Group [G] Time [T] Statistically signiﬁcant differences
[estimated effect size]
Time 1 [T1] Time 2 [T2]
Mean [SD] Mean [SD]
HbA1C IM [n = 13] 8.33 [1.44] 8.97 [1.92] T: F[1,31] = 10.00, P = 0.003*
DL [n = 20] 7.41 [1.64] 8.02 [1.83]
General quality of life IM [n = 18] 0.61 [0.61] 0.67 [0.97]
[ADDQoL – QI] DL [n = 25] 0.60 [1.04] 0.48 [1.12]
Diabetes speciﬁc quality of life IM [n = 18] 1.22 [1.17] 0.94 [0.94] T: F[1,41] = 8.58, P = 0.006*
[ADDQoL – QII] DL [n = 25] 1.64 [0.95] 1.20 [1.19] [0.36]
Depression IM [n = 18] 13.50 [12.37] 8.94 [12.22] G  T: F[1,40] = 3.40, P = 0.073#
[DASS] DL [n = 24] 14.13 [11.38] 15.83 [12.49] [IM: 0.39 vs. DL: 0.15]
Anxiety IM [n = 18] 9.72 [9.90] 8.56 [10.82] G x T: F[1,40] = 2.98, P = 0.092#
[DASS] DL [n = 24] 10.38 [8.07] 12.04 [9.68] [IM: 0.13 vs. DL: 0.19]
Stress IM [n = 18] 15.06 [11.63] 13.06 [12.54] G x T: F[1,40] = 4.11, P = 0.049#
[DASS] DL [n = 24] 15.96 [10.20] 18.21 [11.68] [IM: 0.17 vs. DL: 0.20]
HbA1C = glycosylated haemoglobin; ADDQoL = Diabetes Quality of Life; DASS = Depression Anxiety Stress Scale.
Effects from Group [G] by Time [T] repeated measures analyses of variance [ANOVAs] are reported: *P < 0.01; #possible trend [P > 0.01 and <0.10].
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The ‘‘phase effects” column in Table 2 refers to overall differ-
ences between pairs of study phases in the delayed and immediate
intervention group.3.3.1. HbA1C
There were no overall differences in haemoglobin A1C between
any pair of study phases.3.3.2. ADDQoL
General quality of life [ADDQoL – QI] scores tended to rise dur-
ing the immediate post-treatment period [P = 0.099], while diabe-
tes speciﬁc quality of life [ADDQoL – QII] was signiﬁcantly poorer
at 3-months [P = 0.006] and, to a lesser extent, 6-months
[P = 0.095], relative to the post-treatment phase, suggesting a
reversal of any initial treatment related beneﬁts.3.3.3. DASS
Modest improvements, of approximately one-third of a stan-
dard deviation, were detected between pre- and post-treatment
for each of the DASS measures [depression, P = 0.003; anxiety,
P = 0.001; stress, P = 0.004], which largely remained at 3-months
[depression, P = 0.019; anxiety, P = 0.018; stress, P = 0.012]. How-
ever, comparisons between post-treatment and 6-months sug-
gested that there was a tendency for depression [P = 0.082] and
anxiety [P = 0.056] symptoms to re-emerge.3.4. Effect of delaying treatment [Table 2]
The ‘‘interaction effects” column in Table 2 documents the
extent to which delaying treatment impacted on the differences
between pairs of study phases.3.4.1. HbA1C
Considering the rise in HbA1C detected between time 1 and
time 2 [see Table 1], there was an unexpected post-treatment ben-
eﬁt to the delayed group, relative to those receiving immediate
treatment [P = 0.002]. The DL group experienced a fall in HbA1C
of 0.93% [N = 14] compared with a rise of 0.46% among the IM
group [N = 15].3.4.2. ADDQoL
As shown in Table 2, diabetes speciﬁc quality of life [ADDQoL –
QII] changed little among the DL group. However, there was a ten-
dency for the IM group to deteriorate between post-treatment and
3-months [P = 0.049].
3.4.3. DASS
On the DASS anxiety [P = 0.032] and stress [P = 0.093] measures,
there was a tendency for the DL group to experience a more
marked reduction in symptoms between pre- and post-treatment,
as well as between pre-treatment and 3-months on the anxiety
measure [P = 0.054]. However, this treatment beneﬁt was rela-
tively short-term, as anxiety scores at 6-months were higher
among the DL group than at post-test [P = 0.056] or 3-months
[P = 0.069] relative to the IM group, who displayed similar scores
at post-treatment and 6-months.
As the primary focus of the study was on treatment efﬁcacy, the
ITT analyses were regarded as secondary. All of the planned com-
parisons reported in Table 1 retained comparable levels of statisti-
cal signiﬁcance after imputation of missing data. Likewise, all of
the statistically signiﬁcant effects in Table 2 remained signiﬁcant
in the ITT analyses. However, probably because of the high loss
to follow-up, 7 of the 13 ‘‘trends” identiﬁed in Table 2 would not
have remained in that category based on the ITT analyses, all of
which involved comparisons with the post-treatment phase.4. Discussion
This preliminary study was limited by its relatively small sam-
ple size, with recruitment restricted to a public tertiary clinic set-
ting. Small numbers, and missing data at follow-up, limit
conﬁdence in the study’s ﬁndings. On the other hand, acceptability
of the program was high, with 64% of participants completing ini-
tial and ﬁnal assessments and providing exceptionally positive
feedback, with overwhelming requests for additional CBT pro-
grams with increased numbers of sessions of longer duration.
Participants in the CBT program tended to improve on all three
psychological domains [i.e., depression, anxiety and stress], with
initial reductions of approximately one-third of a standard devia-
tion. On average, DASS scores tended to drop from the moderate
to the normal range initially, and then to drift upwards to the mild
range over time, suggesting more intensive or longer interventions
may be needed to produce sustained beneﬁts. General and diabetes
Table 2
Analysis of differences between treatment phases: CBT program [immediate, IM] vs. waiting list [delayed, DL].
Outcome measure Group [G] Phase [all available data] Statistically signiﬁcant d erences [Estimated effect size]
Pre [PR] Post [PO] 3 months [3 M] 6 months [6 M] Phase effects Interaction effects
Mean [SD, n] Mean [SD, n] Mean [SD, n] Mean [SD, n]
HbA1C IM 8.23 [1.64, 24] 8.69 [1.95, 15] 8.98 [2.06, 8] 8.78 [1.29, 12] G  PR vs. PO: F[1,24] = 9.06, P = 0.002*
DL 7.90 [1.74, 23] 6.97 [1.24, 14] 6.90 [1.01, 13] 6.99 [0.93, 10]
OV 8.06 [1.68, 47] 7.86 [1.84, 29] 7.69 [1.78, 21] 7.97 [1.44, 22]
General quality of life
[ADDQoL – QI]
IM 0.55 [0.69, 29] 0.67 [0.97, 18] 0.38 [1.19, 13] 0.67 [1.05, 15] PR < PO: F[1,32] = 2.89, P = .099#
[0.26]
DL 0.38 [1.20, 26] 1.00 [1.03, 16] 0.87 [0.83, 15] 0.92 [1.12, 13]
OV 0.47 [0.96, 55] 0.82 [1.00, 34] 0.64 [1.03, 28] 0.79 [1.07, 28]
Diabetes speciﬁc quality of life
[ADDQoL – QII]
IM 1.45 [1.02, 29] 0.94 [0.94, 18] 1.31 [1.03, 13] 1.19 [0.75, 16] PO > 3 M: F[1,23] = 9.11, P 0.006*
[0.23]
G  PO vs. 3 M: F[1,23] = 4.31, P = 0.049#
[IM: 0.41 vs. DL: 0.07]
DL 1.23 [1.18, 26] 1.19 [1.11, 16] 1.27 [1.10, 15] 1.23 [1.09, 13] PO > 6 M: F[1,26] = 3.00, P 0.095#
[0.22]
OV 1.35 [1.09, 55] 1.06 [1.01, 34] 1.29 [1.05, 28] 1.21 [0.90, 29]
Depression
[DASS]
IM 15.31 [11.98, 29] 8.94 [12.22, 18] 13.29 [13.62, 14] 9.94 [11.09, 16] PR > PO: F[1,31] = 10.27, P 0.003*
[0.39]
DL 16.24 [12.39, 25] 8.25 [8.43, 16] 7.47 [7.72, 15] 10.00 [11.61, 13] PR > 3 M: F[1,27] = 6.24, P 0.019#
[0.34]
OV 15.74 [12.07, 54] 8.62 [10.46, 34] 10.28 [11.16, 29] 9.97 [11.12, 29] PO < 6 M: F[1,26] = 3.27, P 0.082#
[0.12]
Anxiety
[DASS]
IM 11.66 [9.48, 29] 8.56 [10.82, 18] 10.86 [10.44, 14] 8.44 [10.00, 16] PR > PO: F[1,31] = 12.26, P 0.001**
[0.34]
G  PR vs. PO: F[1,31] = 5.04, P = 0.032#
[IM: 0.13 vs. DL: 0.60]
DL 12.00 [9.47, 25] 4.56 [3.74, 16] 6.33 [7.35, 15] 9.46 [9.13, 13] PR > 3 M: F[1,27] = 6.34, P 0.018#
[0.25]
G  PR vs. 3 M: F[1,27] = 4.06, P = 0.054#
[IM: 0.05 vs. DL: 0.43]
OV 11.81 [9.39, 54] 6.68 [8.41, 34] 8.52 [9.11, 29] 8.90 [9.47, 29] PO < 6 M: F[1,26] = 4.01, P 0.056#
[0.18]
G  PO vs. 6 M: F[1,26] = 4.01, P = 0.056#
[IM: 0.00 vs. DL: 0.43]
G  3 M vs. 6 M: F[1,22] = 3.66, P = 0.069#
[IM: 0.09 vs. DL: 0.32]
Stress
[DASS]
IM 17.14 [11.20, 29] 13.06 [12.54, 18] 15.57 [12.81, 14] 13.31 [11.30, 16] PR > PO: F[1,31] = 9.95, P = .004*
[0.37]
G  PR vs. PO: F[1,31] = 3.00, P = 0.093#
[IM: 0.17 vs. DL: 0.60]
DL 18.48 [11.52, 25] 10.44 [10.11, 16] 12.07 [12.52, 15] 13.46 [11.49, 13] PR > 3 M: F[1,27] = 7.29, P 0.012#
[0.33]
OV 17.76 [11.26, 54] 11.82 [11.37, 34] 13.76 [12.56, 29] 13.38 [11.18, 29]
OV = overall [IM + DL]; HbA1C = glycosylated haemoglobin; ADDQoL = Diabetes Quality of Life; DASS = Depression Anxiety Stress Scale. Effects from planned comparisons an lysis of [pair-wise] differences between phases by Group
[G] are reported [from repeated measures ANOVAs]: *P < 0.01; **P < 0.001; #possible trend [P > 0.01 and <0.10].
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spite the fact that actual diabetic control worsened.
Interestingly, the delayed treatment group unexpectedly de-
rived more beneﬁt from treatment, at least initially, with greater
improvements in depression, anxiety and stress than the immedi-
ate treatment group. They also had a reduction in HbA1C levels
whilst the other group’s HbA1C rose. This may reﬂect treatment
of undiagnosed psychiatric co morbidity by other clinicians in
the intervening period. It is also possible that waiting and being
under observation inﬂuenced the participants’ motivation. Alterna-
tively, those allocated to the delayed group may have experienced
a longer period of distress prior to receiving treatment and, devel-
oped a different set of treatment needs, expectations or prepared-
ness. Against this during follow-up the delayed treatment group
tended to experience a worsening on all of the psychological do-
mains. Moreover, there were no signiﬁcant differences between
pre-treatment and the 6-month follow-up on any of the measures
assessed.
Future research is encouraged to determine, ﬁrstly, whether
these preliminary results are reproducible in similar and/or differ-
ent clinical settings and, secondly, whether a delayed intervention
is more efﬁcacious than an immediate intervention A stepped care
approach may be worth considering, for example, by offering fur-
ther participation in the group program to those who showed an
initial post-treatment beneﬁt but declined substantially by the 3-
month follow-up.
Consideration also needs to be given to identifying selection/
exclusion criteria and measures to enhance program completion.
It may be desirable to stratify individuals into clinically similar
groups with respect to severity of depression, anxiety and stress
scores and then to target the intervention to those at or above agiven severity score, r to make best use of limited resources. It
would also be desirable to compare different CBT delivery methods
[e.g., individual, group, computer, internet based] and modes of
support [e.g., face to face, telephone, email] by various health pro-
fessionals [e.g., diabetes nurse educators, practice nurses, psychol-
ogists, social workers, doctors].References
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